CN105497032B - A kind of piperacillin sodium injection sulbactam sodium composition - Google Patents
A kind of piperacillin sodium injection sulbactam sodium composition Download PDFInfo
- Publication number
- CN105497032B CN105497032B CN201610011133.8A CN201610011133A CN105497032B CN 105497032 B CN105497032 B CN 105497032B CN 201610011133 A CN201610011133 A CN 201610011133A CN 105497032 B CN105497032 B CN 105497032B
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- sodium
- injection
- piperacillin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002347 injection Methods 0.000 title claims abstract description 27
- 239000007924 injection Substances 0.000 title claims abstract description 27
- 229960000614 sulbactam sodium Drugs 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 title claims abstract description 9
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 title claims abstract description 9
- 229960005264 piperacillin sodium Drugs 0.000 title claims abstract description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 14
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 14
- 229960005256 sulbactam Drugs 0.000 claims abstract description 9
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims abstract description 9
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004471 Glycine Substances 0.000 claims abstract description 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 7
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229920000136 polysorbate Polymers 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 229920002721 polycyanoacrylate Polymers 0.000 claims description 2
- 229920005643 polyisobutyl cyanoacrylate Polymers 0.000 claims description 2
- -1 poly- cyanacrylate Chemical compound 0.000 claims 1
- ZTYMNUBYYQNBFP-UHFFFAOYSA-N propyl 2-cyanoprop-2-enoate Chemical compound CCCOC(=O)C(=C)C#N ZTYMNUBYYQNBFP-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- IJVRPNIWWODHHA-UHFFFAOYSA-N 2-cyanoprop-2-enoic acid Chemical compound OC(=O)C(=C)C#N IJVRPNIWWODHHA-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- JHECKPXUCKQCSH-UHFFFAOYSA-J calcium;disodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydrate Chemical compound O.[Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JHECKPXUCKQCSH-UHFFFAOYSA-J 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical group S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 229960003585 cefmetazole Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- PNXMTCDJUBJHQJ-UHFFFAOYSA-N propyl prop-2-enoate Chemical compound CCCOC(=O)C=C PNXMTCDJUBJHQJ-UHFFFAOYSA-N 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of piperacillin sodium injection sulbactam sodium composition, containing avocin, sulbactam, Polyalkylcyanoacrylanano, polyvinylpyrrolidone, trehalose, glycine etc., have the characteristics that solubility is good, good stability.
Description
Technical field
The present invention relates to a kind of piperacillin sodium injection sulbactam sodium compositions.
Background technology
Avocin is a kind of penicillin antibiotics, plays sterilization by interfering the synthesis of bacteria cell wall and makees
With being widely used in the prevention and treatment of the microbial various infectious diseases of Grain-negative.Due to containing beta-lactam nucleus, easily
Drug resistance is generated by bacteriogenic beta-lactam enzyme hydrolysis.Sulbactam is beta-lactamase inhibitor, for golden yellow
Beta-lactamase has irreversible Reverse transcriptase caused by staphylococcus and most gram-negative bacterias, therefore sulbactam is normal
It is combined with penicillins or Cephalosporins, there is good antibacterial to act synergistically.
Piperacillin-sulbactam sodium compound preparation quantity is big, curative for effect, the good and most of cephalo of market prospects
Bacteriums antibiotic is the same, is made by avocin and the packing of sulbactam sterile raw material or freeze-drying.There are one for it
Common defect is exactly that preparation stabilization is poor, the quality requirement that cannot be satisfied the prescriptive period.
Invention content
The present invention provides a kind of piperacillin-sulbactam sodium sterile powder injection, which has solubility good, stable
The features such as property is good, overcomes the deficiencies in the prior art.
The technical scheme is that：
A kind of piperacillin sodium injection sulbactam sodium composition, it is characterised in that the weight of each component in the composition
Number is：
4 parts by weight of avocin；
1 parts by weight of sulbactam；
Polyalkylcyanoacrylanano 2-6 parts by weight；
Polyvinylpyrrolidone 0.5-1 parts by weight；
Trehalose 5-10 parts by weight；
Glycine 5-10 parts by weight；
Tween 1-2 parts by weight.
In the inventive solutions, the Polyalkylcyanoacrylanano, it is preferable that be poly- alpha-cyanoacrylate first
Ester, poly- cyanacrylate, paracyanogen base propyl acrylate, n-butyl polycyanoacrylate, in Polyisobutyl cyanoacrylate
One kind；
The preferred Tween 80 of tween or polysorbas20 as a preferred technical solution,；
The PVP is selected from one kind in PVPk10, PVPk17 or PVPk30 as a preferred technical solution,.
Antioxidant, pH adjusting agent or EDTA calcium can also be added in the composition as a preferred technical solution,
One or more of.
Such as above-mentioned arbitrary technical solution, the composition is powder-injection.
Polyalkylcyanoacrylanano is nanoparticle carrier material in the pharmaceutical composition of the present invention, and trehalose can be with
Increase and redissolves speed；Glycine is used as excipient and frozen-dried supporting agent, and polyvinylpyrrolidone（PVP）Have simultaneously
Have as the decorative material for influencing microballoon release and adjusts the active effect of microsphere surface；Tween is used as surfactant.
The present invention also provides a kind of preparation method of the pharmaceutical composition of cefmetazole for injection and potassium clavulanate, packets
Include following steps：
(1) each component is weighed by formula rate：
(2) avocin and sulbactam are sequentially added in water for injection, poly- cyanoacrylate is added after stirring and dissolving
Acid alkyl ester, tween and polyvinylpyrrolidone continue to stir 3h, and trehalose and glycine is added to being completely dissolved, adjusts pH
To 5-7,0.22 μm of filter membrane is sterile filtered；
(3) it dispenses, freeze-drying.
The method of the freeze-drying includes the following steps：
A, the pre-freeze of product：It is 20 ~ 35% that feed liquid to be dried, which is diluted to mass concentration, and -30 are cooled to rapidly in 1 ~ 2h
DEG C~-40 DEG C, feed liquid becomes block structure；
B, it anneals：Above-mentioned lump material is warming up to -10 ~ 0 DEG C in 4-5h, be then cooled to rapidly in 0.5-1h -
30 DEG C~-40 DEG C, material becomes surface irregularity, the internal loose ice-like structure for having a large amount of perforation holes；
C, lyophilization：Vacuum system is opened, control vacuum degree slowly rises, so that vacuum degree reaches 20Pa in 30min；
Open heating so that the temperature of material is to slowly warm up to 0 ~ 10 DEG C in 2-4h by -30 DEG C~-40 DEG C, and material becomes pine at this time
Scattered powder maintains 2-5h at such a temperature；
D, parsing-desiccation：Above-mentioned material powders are brought rapidly up 40-45 DEG C in 0.5 ~ 1.5h, and maintain the temperature
Lower 0.5 ~ 1h, closes vacuum system so that pressure is slowly restored to normal pressure, obtains the freeze-dried powder of material；
E, it encapsulates：In dry environments, the product after above-mentioned freeze-drying is loaded into closed container rapidly, and taken out rapidly true
It is empty or packed after being passed through nitrogen.
The present invention also provides a kind of piperacillin sodium injection sulbactam sodium compositions in the medicine for preparing treatment bacterium infection
Purposes in object.
Compared with the prior art, piperacillin sodium injection sulbactam sodium composition provided by the invention and preparation method thereof,
It has the following advantages：
1, stability is good：The pharmaceutical composition of piperacillin-sulbactam sodium provided by the invention is to be wrapped up and inhaled
It is attached in nanoparticulate carriers material, active constituent is effectively protected, therefore the more excellent commercially available product of stability is more excellent.Accelerate June and
Long-time stability investigate result and also indicate that solution colour, pH value, related substance, content without significant change, and encapsulation rate is small,
Greatly improve medicine stability.
2, solubility is good：The use of Freeze Drying Technique effectively avoids the degradation of polymeric material, drug leakage or medicine
Object is degraded, and keeps drug preservation condition range wider, and excipient, which is added, before being freeze-dried keeps the solubility of this product good, after redissolution
The various physicochemical properties of drug are preceding essentially identical with freeze-drying.
Specific implementation mode
The present invention is described in further detail With reference to embodiment.But this should not be interpreted as to the present invention
The range of above-mentioned theme is only limitted to following embodiments.
1 powder ampoule agent for injection of embodiment and its preparation
Formula：
Avocin 400g；
Sulbactam 100g；
Polyalkylcyanoacrylanano 200g；
Polyvinylpyrrolidone（PVP） 60g；
Trehalose 500g；
Glycine 500g；
Tween 80 100g.
Avocin and sulbactam are sequentially added in 2.5L waters for injection, paracyanogen base is added after stirring at normal temperature dissolving
Alkyl acrylate, Tween 80 and PVP continue to stir 3h, trehalose and glycine are added, adds 0.5L waters for injection, stir
To being completely dissolved, pH to 5-7 is adjusted, 0.22 μm of filter membrane is sterile filtered；Filtrate is dispensed in the cillin bottle to sterilizing.
Above-mentioned material is put into freeze dryer, refrigeration is opened, is cooled to -40 DEG C rapidly in 1h, feed liquid becomes block structure.It will
Above-mentioned lump material is warming up to -10 DEG C in 3h, is then cooled to -40 DEG C rapidly in 0.5h, material becomes concave-convex surface not
Flat, the internal loose ice-like structure for having a large amount of perforation holes.Vacuum system is opened, control vacuum degree slowly rises, makes in 30min
It obtains vacuum degree and reaches 10Pa.Heating is opened, the temperature of material is made to be to slowly warm up to 10 DEG C by -40 DEG C in 3h, material becomes at this time
For loose powder, 3h at such a temperature is maintained.Above-mentioned material powders are brought rapidly up in 1h to 45 DEG C, and maintain the temperature
The lower 1h of degree, closes vacuum system so that pressure is slowly restored to normal pressure, is sealed with sterile rubber plug, then pricked with sterile aluminium lid
Lid seals to obtain the final product.
2 droplet measurement of embodiment
The injection of Example 1 is dissolved in water into solution of every 1ml containing 1mg grams of avocin, with laser light scattering grain
Instrument is spent to measure.
As a result：Piperacillin-sulbactam sodium injection prepared by embodiment 1 is in microspheroidal, and particle diameter distribution is uniform, all
Grain size is between 50-120nm.
Embodiment 3：Encapsulation rate detects
The injection of piperacillin-sulbactam sodium is dissolved in water into the solution of every 1ml recipe comprising piperacillins sodium 1mg, with
The speed of 5000r/min centrifuges 25min, takes supernatant 1ml, is dissolved with methanol, measures the content of avocin.
Dose in encapsulation rate=microballoon/（The dose in dose+medium in microballoon）×100%
As a result：The encapsulation rate of injection prepared by embodiment 1, between 88%-95%.
Embodiment 4：Solubility is investigated
Randomly select 8 bottles, number 1-8 of injection in embodiment 1, the sample number into spectrum 9 after physical mixed, by clinical application
Dissolving method, be injected separately into 10ml waters for injection, shaked on eddy mixer, with dissolve completely it is clear and bright for index, calculate
Solution rate
| Sample | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| Dissolution time/second | 16 | 17 | 15 | 15 | 17 | 16 | 16 | 15 | 29 |
The experimental results showed that the redissolution speed of the injection of the present invention is substantially better than the injection of direct packaging.
Embodiment 5：Study on the stability
Sample prepared by embodiment 1（Number is A）The injection of packing is directly mixed with raw material（Number is B）It sets respectively
6 months under the conditions of 40 DEG C of high temperature, relative humidity 75% ± 5%, acceleration investigation is carried out.
When experiment shows Acceleration study 6 months, the injection character of direct packaging becomes pale yellow powder, and pH declines bright
Aobvious, content reduces more；And injection appearance character prepared by the present invention, pH, content have no significant change, to demonstrate this
The stability of invention injection is more prominent.
Claims (2)
1. a kind of piperacillin sodium injection sulbactam sodium composition, it is characterised in that the parts by weight of each component in the composition
Number is：
4 parts by weight of avocin；
1 parts by weight of sulbactam；
Polyalkylcyanoacrylanano 2-6 parts by weight；
Polyvinylpyrrolidone 0.5-1 parts by weight；
Trehalose 5-10 parts by weight；
Glycine 5-10 parts by weight；
Tween 1-2 parts by weight；
The Polyalkylcyanoacrylanano is selected from poly- Methyl 2-cyanoacrylate, poly- cyanacrylate, poly- alpha-cyanoacrylate
Propyl ester, n-butyl polycyanoacrylate, one kind in Polyisobutyl cyanoacrylate；
The tween is selected from Tween 80 or polysorbas20；
The polyvinylpyrrolidone is selected from one kind in PVP k10, PVP k17 or PVP k30.
2. piperacillin sodium injection sulbactam sodium composition as described in claim 1 is in the drug for preparing treatment bacterium infection
In purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610011133.8A CN105497032B (en) | 2016-01-10 | 2016-01-10 | A kind of piperacillin sodium injection sulbactam sodium composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610011133.8A CN105497032B (en) | 2016-01-10 | 2016-01-10 | A kind of piperacillin sodium injection sulbactam sodium composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105497032A CN105497032A (en) | 2016-04-20 |
| CN105497032B true CN105497032B (en) | 2018-09-18 |
Family
ID=55705593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610011133.8A Active CN105497032B (en) | 2016-01-10 | 2016-01-10 | A kind of piperacillin sodium injection sulbactam sodium composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105497032B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101269072A (en) * | 2008-05-09 | 2008-09-24 | 郑飞雄 | Pharmaceutical composition containing beta-lactamase restrainer and piperacillin sodium with steady content and preparation method thereof |
| CN101632671A (en) * | 2009-08-18 | 2010-01-27 | 海南永田药物研究院有限公司 | Suspensoid powder injection of piperacillin sodium sulbactam sodium medicine composition and novel application thereof |
| CN103271925A (en) * | 2013-06-05 | 2013-09-04 | 重庆福安药业集团庆余堂制药有限公司 | Injection-use pharmaceutical composition comprising cefmetazole sodium and clavulanate potassium |
-
2016
- 2016-01-10 CN CN201610011133.8A patent/CN105497032B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101269072A (en) * | 2008-05-09 | 2008-09-24 | 郑飞雄 | Pharmaceutical composition containing beta-lactamase restrainer and piperacillin sodium with steady content and preparation method thereof |
| CN101632671A (en) * | 2009-08-18 | 2010-01-27 | 海南永田药物研究院有限公司 | Suspensoid powder injection of piperacillin sodium sulbactam sodium medicine composition and novel application thereof |
| CN103271925A (en) * | 2013-06-05 | 2013-09-04 | 重庆福安药业集团庆余堂制药有限公司 | Injection-use pharmaceutical composition comprising cefmetazole sodium and clavulanate potassium |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105497032A (en) | 2016-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2062582B1 (en) | Antibiotic composition comprising beta-lactam antibiotics, aminoglycosides and buffers | |
| EP2062581B1 (en) | The antibiotics composition comprising beta-lactam antibiotics and ionic chelating agents | |
| RU2322980C2 (en) | Piperacillin and tazobactam-containing compositions used for injection | |
| KR101763195B1 (en) | Dry powder vancomycin compositions and associated methods | |
| CN105560243B (en) | A kind of preparation method of piperacillin sodium injection sulbactam sodium composition | |
| Sousa et al. | Development of a novel AMX-loaded PLGA/zein microsphere for root canal disinfection | |
| CN109475508A (en) | The preparation method of the instant film containing bioactive materials of thermal stability with enhancing | |
| WO2004098643A1 (en) | Compositions containing piperacillin and tazobactam useful for injection | |
| CN102292079A (en) | Compositions and methods of treatment comprising ceftaroline | |
| BRPI0211453B1 (en) | COMPOSITION OF NON-PATHOGENIC BACTERIA SPORTS OF GENRE BACILLUS ADSORTED IN A MATRIX AND THEIR OBTAINING PROCESS | |
| CN105497032B (en) | A kind of piperacillin sodium injection sulbactam sodium composition | |
| CN103271925B (en) | Injection-use pharmaceutical composition comprising cefmetazole sodium and clavulanate potassium | |
| CN102367229B (en) | Ethylenediamine diaceturate compound and pharmaceutical composition thereof | |
| CN101904822B (en) | Faropenem sodium freeze-drying powder and preparation method thereof | |
| CN102727451B (en) | Cefmetazole-containing pharmaceutical composition | |
| CN101804060B (en) | Microsphere injection of ceftriaxone sodium/tazobactam sodium drug composition | |
| CN101361729A (en) | Thiamphenicol aminoacetate hydrochloride sterile freeze-drying preparation for injection and preparation method thereof | |
| CN103271924B (en) | Injection-use pharmaceutical composition comprising cefathiamidine and tazobactam sodium | |
| CN106176722A (en) | A kind of imipenem for injection cilastatin sodium aseptic powdery preparation and preparation method thereof | |
| CN104524585A (en) | Cefathiamidine composition | |
| CN102988954B (en) | Medicinal composition containing thymopentin compound | |
| CN114159432B (en) | Tebucillin sodium clavulanate potassium pharmaceutical composition and preparation method thereof | |
| CN102258487B (en) | Meropenem liposome injection | |
| CN102716096B (en) | Medicinal composition containing cefotiam hydrochloride | |
| CN104324036A (en) | Drug composition of sulfamonomethoxine sodium with synergistic antibacterial effect for injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |